Viatris completes Pacira acquisition, projects $100M revenue boost

Viatris has completed its acquisition of Pacira BioSciences, a non-opioid pain management company. The transaction closed Nov. 17, after Viatris accepted for payment approximately 32,929,780 shares, representing approximately 66.46% of Pacira’s outstanding stock, tendered at $36.50 per share in cash. Viatris then merged Pacira’s remaining shares into the deal without a Pacira stockholder vote, converting […] The post Viatris completes Pacira acquisition, projects $100M revenue boost appear...

Original Source

Read the full article at Beckershospitalreview →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.